Radiation Therapy for Uterine Cervical Cancer With Lung Metastases Including Oligometastases

Area of Science:

• Oncology
• Radiation Oncology
• Gynecologic Oncology

Background:

• Stage IVB uterine cervical cancer (UCC) with lung metastases presents a significant clinical challenge.
• Recent data on the role of radiation therapy (RT) in this specific patient group is limited.

Purpose of the Study:

• To evaluate the efficacy and safety of radiation therapy (RT) in patients with stage IVB uterine cervical cancer (UCC) and lung metastases.
• To identify prognostic factors influencing survival in this cohort.

Main Methods:

• Retrospective analysis of 23 consecutive patients with stage IVB UCC and lung metastases who received pelvic RT.
• Categorization of patients based on the number and laterality of lung metastases, and presence of other distant metastases.

Main Results:

• Radiation therapy (RT) was completed without interruption by 39.1% of patients.
• The 1-year primary progression-free rate was 95.2%, with an overall survival rate of 47.2% (median survival: 9 months).
• Favorable prognostic factors for survival included oligometastases (≤4 lung metastases), unilateral lung involvement, primary tumor diameter <100 mm, and ECOG performance status <1.

Conclusions:

• Radiation therapy (RT) demonstrates safety and effectiveness as a treatment modality for stage IVB uterine cervical cancer (UCC) patients with lung metastases.
• Identifying prognostic factors can aid in patient selection and treatment planning.